Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guangzhou Kingmed Diagnostics Group Co's quarterly Accounts Payable
declined
from Sep. 2025 (¥1,561 Mil) to Dec. 2025 (¥1,486 Mil) and
declined
from Dec. 2025 (¥1,486 Mil) to Mar. 2026 (¥1,478 Mil).
Guangzhou Kingmed Diagnostics Group Co's annual Accounts Payable
declined
from Dec. 2023 (¥2,065 Mil) to Dec. 2024 (¥1,716 Mil) and
declined
from Dec. 2024 (¥1,716 Mil) to Dec. 2025 (¥1,486 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Kingmed Diagnostics Group Co Accounts Payable Chart
Guangzhou Kingmed Diagnostics Group Co Annual Data
Guangzhou Kingmed Diagnostics Group Co Accounts Payable Calculation
Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.
Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) has a Accounts Payable of ¥1,478 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Guangzhou Kingmed Diagnostics Group Co and its competitors.
Is Guangzhou Kingmed Diagnostics Group Co's Accounts Payable too high?
Guangzhou Kingmed Diagnostics Group Co's current Accounts Payable is ¥1,478 Mil. Overall, Guangzhou Kingmed Diagnostics Group Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Kingmed Diagnostics Group Co's Accounts Payable compare to TMO and DHR?
Guangzhou Kingmed Diagnostics Group Co's Accounts Payable of ¥1,478 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Medical Diagnostics & Research company?
A good Accounts Payable depends on the Medical Diagnostics & Research industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Guangzhou Kingmed Diagnostics Group Co and its competitors. Guangzhou Kingmed Diagnostics Group Co's current Accounts Payable is ¥1,478 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Kingmed Diagnostics Group Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) is currently considered Fairly Valued. The stock's GF Value™ is ¥28.13, compared to a current price of ¥30.54 — trading 8.6% above its estimated fair value. The current Accounts Payable is ¥1,478 Mil. Guangzhou Kingmed Diagnostics Group Co's overall GF Score™ is 74/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Guangzhou Kingmed Diagnostics Group Co (SHSE:603882), the current Accounts Payable is ¥1,478 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) Overvalued in 2026?
Based on GuruFocus' analysis, Guangzhou Kingmed Diagnostics Group Co stock appears to be overvalued.
The current stock price of ¥30.54 is trading 8.6% above its estimated GF Value™ of ¥28.13.
GuruFocus considers Guangzhou Kingmed Diagnostics Group Co to be Fairly Valued.
Key valuation signals for SHSE:603882:
Accounts Payable: ¥1,478 Mil
GF Value™: ¥28.13 vs. price of ¥30.54 (8.6% above fair value)
No single metric tells the full story. See the SHSE:603882 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 1994, KingMed is the largest independent clinical laboratory in China. It was listed on the Shanghai Stock Exchange in 2017. As of 2024, KingMed has 50 centralized labs and provides over 4000 test items. Over 90% of its total revenue comes from clinical diagnostics. Furthermore, KingMed has been actively investing in its cold chain logistics. Its service network covers the most intensely populated areas in China.
74GF Score
Get the complete analysis for SHSE:603882
Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603882 has been successfully added to your 
